Liv H. Johannessen, Ph.D.
Affiliations: | 2007-2012 | Cancer Inflammation Program | National Cancer Institute at Frederick, MD 21702 USA, Frederick, MD, United States |
| 2012- | BCMP | Harvard University, Cambridge, MA, United States |
Area:
CDKs, Transcription, ImmunologyGoogle:
"Liv Johannessen"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Arnett A, Moo KG, Flynn KJ, et al. (2021) The CDK8 inhibitor DCA promotes a tolerogenic chemical immunophenotype in CD4 T cells via a novel CDK8-GATA3-FOXP3 pathway. Molecular and Cellular Biology. MCB0008521 |
| Johannessen L, Ke N, Sawant P, et al. (2020) Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer. Journal of Clinical Oncology. 38: 3585-3585 |
| Hu S, Marineau JJ, Rajagopal N, et al. (2019) Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Research |
| Ke N, Johannessen L, Rajagopal N, et al. (2019) Abstract 4409: Prospective identification of RB pathway alterations predict response to SY-1365, a selective CDK7 inhibitor, in a panel of high-grade serous ovarian cancer (HGSOC) patient derived xenograft (PDX) models Cancer Research. 79: 4409-4409 |
| Johannessen LH, Hu S, Ke N, et al. (2019) Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications Molecular Cancer Therapeutics. 18 |
| Hatcher JM, Wang ES, Johannessen L, et al. (2018) Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. Acs Medicinal Chemistry Letters. 9: 540-545 |
| Konstantinopoulos PA, Hodgson G, Rajagopal N, et al. (2018) Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo Cancer Research. 78: 1525-1525 |
| Johannessen L, Sundberg TB, O'Connell DJ, et al. (2017) Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nature Chemical Biology |
| Sundberg TB, Liang Y, Wu H, et al. (2016) Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function In Vivo. Acs Chemical Biology |
| Tan L, Akahane K, McNally R, et al. (2015) Development of Selective Covalent JAK3 Inhibitors. Journal of Medicinal Chemistry |